Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16451307 | 0.88 | OPRM1 (1.00) | OPRM1DRD3 | |
| SCHEMBL8579408 | 0.85 | OPRM1 (0.73) | OPRM1DRD3KCNA3KCNH2OPRD1 | |
| Hydrochloric Acid SCHEMBL9065401 | 0.84 | OPRM1 (0.72) | OPRM1DRD3KCNA3KCNH2OPRD1 | |
| SCHEMBL8216333 | 0.81 | OPRM1 (0.67) | OPRM1KCNA3OPRD1OPRK1 | |
| SCHEMBL9064652 | 0.80 | OPRM1 (0.66) | OPRM1DRD3KCNA3KCNH2 | |
| SCHEMBL9065208 | 0.79 | OPRM1 (0.65) | OPRM1DRD3KCNA3OPRD1OPRK1 | |
| SCHEMBL8187800 | 0.79 | OPRM1 (0.65) | OPRM1KCNA3OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9064512 | 0.79 | OPRM1 (0.75) | OPRM1KCNA3KCNH2OPRD1OPRK1 | |
| SCHEMBL9437085 | 0.79 | OPRM1 (0.65) | OPRM1DRD3 | |
| SCHEMBL11747588 | 0.75 | OPRM1 (0.59) | OPRM1DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235864-A1 | COATED NEEDLE ADMINISTRATION SYSTEMS | EVOLUS, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250177430-A1 | Compositions Comprising NAD+ and Associated Methods of Treatment | WORKMAN DAVID HENRY (US) | 2025-06-05 | — | — | US | claimed |
| EP-3703802-B9 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-12-04 | — | — | EP | claimed |
| EP-3703802-B1 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-10-16 | — | — | EP | claimed |
| WO-2023187664-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IMMUNE SYSTEM MEDIATED DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-10-05 | — | — | WO | claimed |
| WO-2023154844-A2 | COMPOSITIONS COMPRISING NAD+ AND ASSOCIATED METHODS OF TREATMENT | WORKMAN DAVID HENRY (US) | 2023-08-17 | — | — | WO | claimed |
| US-11471503-B2 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-10-18 | — | — | US | claimed |
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2022-03-31 | — | — | US | claimed |
| EP-3914246-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2021-12-01 | — | — | EP | claimed |
| US-20200368309-A1 | USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAIN | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-11-26 | — | — | US | claimed |
| EP-0999839-B1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | LEVIN BRUCE H (US) | 2004-06-23 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20020127249-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | BERGENSTAHL BJORN (SE) | 2002-09-12 | — | — | US | claimed |
| US-6432986-B2 | INTRANOSALLY ADMINISTERING OF ANESTHETICS | BHL PATENT HOLDINGS LLC | 2002-08-13 | — | — | US | claimed |
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | BHL PATENT HOLDINGS LLC | 2001-12-27 | — | — | US | claimed |
| WO-2001043733-A2 | COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION | LEVIN BRUCE H (US) | 2001-06-21 | — | — | WO | claimed |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | LEVIN BRUCE H (US) | 2001-06-21 | — | — | US | claimed |
| CN-1284864-A | Novel formulations for the control of pain | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-02-21 | — | — | CN | claimed |
| EP-1033970-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | AstraZeneca AB (SE) | 2000-09-13 | — | — | EP | claimed |
| WO-1999022717-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | ASTRAZENECA AB (SE) | 1999-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | TNNC1, KIT, PDE3A | OPRM1 1213/4885DRD3 4554/4885KCNA3 72/4885 |
| US-20020127249-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | OPRL1, OPRM1, TRPV1 | OPRM1 2/4885DRD3 1865/4885KCNA3 106/4885 |
| US-11471503-B2 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885DRD3 181/4885KCNA3 249/4885 |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | CXCR5, CCL5, C5AR2 | OPRM1 320/4885DRD3 3920/4885KCNA3 2401/4885 |
| US-20200368309-A1 | USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAIN | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885DRD3 181/4885KCNA3 249/4885 |
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | FABP7, ALB, SLC1A2 | OPRM1 304/4885DRD3 1240/4885KCNA3 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.